EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases

Inclusion Criteria: 1. Patients with solid masses (diameter \> 1 cm) in the pancreatic area within the accessible range of endoscopic ultrasound, as indicated by clinical symptoms, laboratory tests, and imaging examinations (MRI, CT, B-ultrasound), who require biopsy to clarify the nature of the lesion. 2. Patients diagnosed with resectable pancreatic cancer, borderline resectable pancreatic cancer, locally advanced pancreatic cancer by imaging(CT/MRI). 3. Newly diagnosed pancreatic cancer patients who have not received radiotherapy or chemotherapy. 4. Signed informed consent form. 5. Patients must be able to comply with the trial requirements. Exclusion Criteria: 1. Patients with other active malignant tumors 2. Patients with coagulation dysfunction (PLT 50,000/mm3, INR \> 1.5; roughly estimated, INR \> 1.5 is approximately equivalent to PT \> 18 seconds) 3. Pregnant women 4. Patients with hemorrhagic diseases 5. Patients with a history of taking anticoagulant drugs such as aspirin and warfarin in the past week 6. Patients with absolute contraindications to EUS examination, a history of acute pancreatitis within the past 2 weeks, a history of gastric surgery, pregnancy, severe diseases, or a history of allergy to anesthetics 7. Patients whose EUS examination was terminated early due to esophageal stenosis, obstruction, large space-occupying lesions, rapid changes in the patient's heart rate or respiratory rate, patient intolerance, or a large amount of food residue, etc. 8. Patients with known hepatitis C virus infection 9. Patients with known human immunodeficiency virus (HIV) infection 10. Patients with imaging examinations, EUS results, etc., suggesting pancreatic cystic space-occupying lesions 11. Patients who have received radiotherapy or chemotherapy 12. Patients with incomplete pathological information, unable to make a clear diagnosis, or unable to sign the informed consent form